What the Research Actually Says About Food-Based Sleep Supplements

The sleep supplement market runs on ambient plausibility. Something is relaxing, something is natural, someone’s grandmother swore by warm milk — and so a product exists. What is harder to find is a straightforward account of which food-derived compounds have been through randomized controlled trials with objective sleep outcomes, and what those trials actually showed.

Five compounds have enough trial-level evidence to warrant serious examination: tart cherry juice, kiwi, glycine, L-theanine, and magnesium. None of them approach the efficacy of melatonin or pharmaceutical sleep aids, and none have been studied at the scale of the major sleep medications. But they are not equivalent to each other, and the differences are worth understanding.

---

Tart cherry juice

The most consistent food-based sleep data is probably for tart cherry juice, which contains a modest amount of melatonin and appears to affect sleep through both melatonin and serotonin precursor pathways.

Pigeon et al. (2010, Journal of Medicinal Food) conducted a randomized, double-blind, crossover trial in adults with chronic insomnia, aged 18–40, comparing two weeks of tart cherry juice to a placebo drink. Outcome measures included actigraphy and the Insomnia Severity Index. The finding: tart cherry juice produced significant reductions in insomnia severity score and in wakefulness after sleep onset, compared to placebo. The effect sizes were modest — the ISI reduction was meaningful but not large — but the design was credible: randomized, double-blind, with objective actigraphy data.

A second trial by Howatson et al. (2012, European Journal of Nutrition) replicated the finding in healthy adults without diagnosed insomnia, using a shorter consumption period (seven days). They found increases in urinary 6-sulfatoxymelatonin (a melatonin metabolite), decreased wakefulness, and increased total sleep time measured by actigraphy. The effect was detectable even in people without a sleep complaint, suggesting it is not purely a ceiling-effect phenomenon.

The proposed mechanism — exogenous melatonin plus tryptophan — is straightforward. Tart cherries contain approximately 13–15 nanograms of melatonin per gram, which is low relative to supplement doses (0.5–5 mg is common in supplements), but higher than nearly any other food. The anti-inflammatory phenolic compounds (particularly anthocyanins) may contribute through indirect pathways, though this has not been isolated experimentally.

What the evidence does not show: dose-response data is thin, optimal timing is poorly studied, and whether the active ingredient is melatonin, the phenolics, or the tryptophan-serotonin pathway is not established. Both trials used tart cherry in juice form; extracts and capsules have not been comparably studied.

---

Kiwi

The kiwi evidence is a single randomized controlled trial with a small sample, which means it should be read as preliminary but not ignored.

Lin et al. (2011, Asia Pacific Journal of Clinical Nutrition) enrolled 24 adults with self-reported sleep disturbances in a four-week study of two kiwi fruits consumed one hour before bedtime. Outcome measures were subjective (Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale) and actigraphic (total sleep time, sleep efficiency, wakefulness after sleep onset). Compared to baseline, participants showed statistically significant improvements across all four measures: sleep onset latency decreased by 35.4%, total sleep time increased by 13.4%, sleep efficiency improved, and wakefulness after sleep onset decreased by 28.9%.

The limitation is the absence of a controlled comparison group in the published analysis — the trial’s design has been questioned, and the effect sizes are unusually large for a food-based intervention. This is either a real signal that warrants replication or a methodological artifact. As of writing, no independent replication has been published.

The proposed mechanisms are broader than for tart cherry: kiwi contains serotonin (which crosses the gut-brain axis in ways that remain contested), folate (low folate is associated with insomnia in epidemiological data), and antioxidants. The multiplicity of hypothesized mechanisms without an established one makes the interpretation harder, not easier.

Two kiwis per night represents a practical intervention with no known downsides. It also represents a poorly replicated finding. These are not contradictory positions to hold simultaneously.

---

Glycine

Glycine is an amino acid with a distinctly different evidence base from the others on this list: it was studied not for sleep onset or maintenance but for subjective morning quality after it was administered the night before.

Bannai et al. (2012, Sleep and Biological Rhythms) administered 3 grams of glycine or placebo to human subjects before sleep in two crossover studies. The primary outcomes were subjective — measures of morning freshness, daytime sleepiness, and fatigue — and the findings were significant: glycine-treated subjects reported meaningfully lower fatigue scores, improved morning freshness, and lower Epworth Sleepiness Scale scores the following day. Objective measures (actigraphy) also showed reduced sleep latency and improved sleep efficiency in the glycine group.

A mechanistic study by the same group proposed that glycine acts by lowering core body temperature through peripheral vasodilation — the same direction as the sleep-onset temperature drop that precedes natural sleep onset. This mechanism is distinct from melatonin pathways and represents a genuinely different point of intervention in sleep architecture.

The glycine literature has one thing the tart cherry and kiwi literature lacks: a credible proposed mechanism with supporting mechanistic data. The sample sizes remain small, but the crossover design is appropriate, and the morning outcomes are measured well.

The practical question is whether 3 grams of glycine supplementation (not dietary glycine, but supplemental) produces effects large enough to matter clinically. The effect sizes in Bannai et al. are meaningful but not dramatic. For someone with significant sleep complaints, glycine is unlikely to be sufficient. For someone with adequate sleep who is managing morning performance, the mechanism is interesting enough to take seriously.

---

L-theanine

L-theanine, an amino acid in green tea, has been studied for sleep primarily in populations with elevated anxiety and in clinical samples with attention and sleep disorders rather than in otherwise healthy adults with insomnia complaints.

Hidese et al. (2019, Nutrients) conducted a randomized, double-blind, placebo-controlled crossover trial of 200 mg L-theanine versus placebo in 30 healthy adults, measuring subjective sleep quality, mood, and cognitive function. The finding: L-theanine produced significant improvements in subjective sleep satisfaction, sleep latency, and anxiety compared to placebo. A functional assessment found improvements in verbal fluency and executive function the morning after.

The mechanistic account is well-developed: L-theanine increases alpha brain wave activity, reduces cortisol response to stress, and appears to modulate GABA and NMDA receptor activity. It crosses the blood-brain barrier efficiently. The anxiolytic effects appear real across multiple trials.

What is harder to establish is whether L-theanine’s sleep benefits are independent of anxiety reduction or downstream of it. In other words: does L-theanine improve sleep quality in people who aren’t anxious? The Hidese et al. study included subjects with baseline anxiety as a selection criterion, which limits generalization. An earlier pilot study by Higashiyama et al. (2011) in boys with attention deficit disorder found L-theanine improved objective sleep quality (actigraphy), but this sample is not representative of the adult population with typical sleep complaints.

The practical profile: L-theanine appears useful for sleep disruption where anxiety is a component. For pure sleep maintenance insomnia in someone with low anxiety, the evidence is thinner.

---

Magnesium

The magnesium evidence is voluminous in epidemiological form (low dietary magnesium is associated with sleep problems across multiple surveys) and sparser in intervention form.

Abbasi et al. (2012, Journal of Research in Medical Sciences) conducted an eight-week, double-blind, placebo-controlled trial of 500 mg magnesium versus placebo in 46 older adults with insomnia. The magnesium group showed significant improvements in insomnia severity, sleep efficiency, sleep time, early morning awakening, serum renin levels, and melatonin concentrations. This is one of the more comprehensive intervention studies in this area: older adults with diagnosed insomnia, double-blind design, eight weeks, multiple outcome measures including objective biochemical markers.

The association between magnesium and sleep runs through multiple pathways: magnesium regulates NMDA receptor activity (relevant to arousal), binds to GABA receptors (promoting relaxation), and appears to influence melatonin production. Magnesium deficiency is common in populations with poor sleep — but whether supplementation in people without deficiency produces the same benefit is not established by the current evidence.

The form of magnesium matters in ways that supplement marketing rarely acknowledges clearly. Magnesium oxide (cheap, common in supplements) is poorly absorbed. Magnesium glycinate and magnesium threonate have better absorption profiles and theoretical advantages for CNS effects. The Abbasi et al. trial used magnesium oxide, which means the effect found was despite lower bioavailability — a finding that either suggests a large underlying effect or that some part of the benefit comes from gut-level mechanisms independent of systemic absorption. The evidence for magnesium glycinate specifically — including its interaction with the glycine amino acid — is examined in detail in Magnesium Glycinate and Sleep.

---

What the evidence base shares

Across these five compounds, several patterns recur:

Sample sizes are small. The Bannai et al. glycine studies used fewer than 20 subjects per condition. Lin et al.’s kiwi study had 24 total. Abbasi et al.’s magnesium trial had 46. These are pilot-scale numbers that support further research rather than definitive conclusions.

Populations are variable. Pigeon et al. used adults with chronic insomnia. Howatson et al. used healthy adults without sleep complaints. Bannai et al. used subjects with sleep complaints but not clinically diagnosed insomnia. Lin et al. used self-reported sleep disturbance. These are not the same populations, and the differences matter for who a result applies to.

Mechanistic data is stronger for some than others. Glycine (core body temperature lowering) and L-theanine (alpha wave activity, cortisol modulation) have better mechanistic accounts than tart cherry (multiple proposed pathways, undifferentiated) and kiwi (multiple hypothesized mechanisms, limited evidence for any).

Effect sizes are modest. None of these compounds produce effects approaching prescription sleep medication or CBT-I. The realistic use case is improving sleep at the margins for people with manageable sleep disruption — not replacing medical treatment for significant insomnia.

---

FAQ

What foods help you sleep better?

The food-based compounds with the most trial-level support are tart cherry juice (two RCTs showing reduced insomnia symptoms and wakefulness after sleep onset), kiwi (one RCT showing improved sleep quality, pending replication), and foods high in glycine (which appears to improve morning freshness and reduce sleep latency via core temperature reduction). Magnesium-rich foods may help populations with dietary magnesium deficiency. L-theanine, found in green tea, has evidence specifically in anxious populations.

Does tart cherry juice actually help sleep?

Two randomized controlled trials — Pigeon et al. (2010, Journal of Medicinal Food) and Howatson et al. (2012, European Journal of Nutrition) — found tart cherry juice improved sleep measures compared to placebo, using actigraphy as an objective outcome. The effect is modest and most pronounced in people with existing sleep disruption. The active compounds appear to be melatonin and possibly serotonin precursors.

Is magnesium good for sleep?

Abbasi et al. (2012) found 500 mg magnesium over eight weeks improved insomnia severity, sleep efficiency, and melatonin levels in older adults with insomnia. Epidemiological data consistently associates low dietary magnesium with poor sleep quality. Whether supplementation helps people with adequate dietary magnesium is less established. Form matters: magnesium glycinate and threonate have better absorption than oxide.

What is the difference between L-theanine and melatonin for sleep?

L-theanine promotes relaxation and reduces anxiety through GABA and alpha wave mechanisms; its sleep benefits appear most pronounced when anxiety is a contributor to sleep disruption. Melatonin is a timing signal that advances or sustains circadian phase; it is most useful for sleep timing problems (jet lag, shift work, delayed sleep phase) rather than sleep maintenance issues. They address different mechanisms and can be used together without pharmacological interaction. For a detailed account of melatonin’s dose, timing, and appropriate use cases, see Melatonin: A Field Guide.